A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs GS 9674 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions
- Acronyms PSC-Phase 2
- Sponsors Gilead Sciences
- 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
- 19 May 2017 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.